Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone. My name is Angela, and I will be your conference operator today. At this time, I would like to welcome you to OVID Therapeutics Business and Pipeline Update Call. This conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's prepared remarks, there will be a question and answer session. At this time, I would like to turn the call over to Victoria Ford. Please proceed. Thank you. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release announcing business and pipeline updates and financial results for the three months and full year ended December 31st, 2025. A copy of the release can be found in the Investor Relations tab on our corporate website, AvidRx.com. As a reminder, during today's call, we'll be making forward-looking statements. Various remarks we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for the purpose of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this call are subject to a number of risks and uncertainties, which could cause our actual results to differ materially from those expressed or implied in such statements. These factors include, but are not limited to, those discussed in our most recent annual report on Form 10-K, and other filings with the Securities and Exchange Commission. Joining me on today's call are Meg Alexander, our President and Chief Executive Officer, and Jeffrey Rona, our Chief Business and Financial Officer. Meg will go over the clinical and business updates we announced this morning, and then Jeff will detail our financial results, followed by a que...